Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
Patient Selection and Assessment Criteria for patient eligibility, medical history and contraindications According to the package insert: Wegovy (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management: YES: adults with an initial body mass index (BMI) of 30 kg/m2 (obesity) or 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity) NO: Patients with a personal or family history of MTC Patients with MEN 2 Patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in semaglutide WARNING & PRECAUTIONS: Risk of the following: Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Hypoglycemia Acute Kidney Injury Hypersensitivity Reactions Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Heart Rate Increase Suicidal Behavior and Ideation ADDITIONAL Patients should be warned about the following: History of type 1 diabetes or diabetic ketoacidosis, as semaglutide is not indicated for these conditions
Similar content being viewed by others Subjects Introduction L-carnitine is an important factor that regulates fatty acid (FA) and glucose metabolism to achieve balanced cellular energy metabolism 1
Learn More Zepbound vials Available via LillyDirect Medication cost billed by LillyDirect A once-weekly injectable GLP-1/GIP dual agonist indicated for the treatment of overweight and obesity
Labeling of drugs with adequate directions for use
US$ 29.05
US$ 20.87
US$ 28.14
US$ 23.66
US$ 28.53
US$ 22.10
US$ 25.47
US$ 26.47
